$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000144702822000019 Filed on March 03, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$3.206M	$10.99M	$2.390M
YoY Change	34.14%	58.92%	47.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.698M	$17.14M	$3.540M
YoY Change	32.71%	16.41%	88.3%
% of Gross Profit
Research & Development	$20.44M	$65.50M	$14.54M
YoY Change	40.56%	32.76%	17.07%
% of Gross Profit
Depreciation & Amortization	$427.0K	$1.800M	$490.0K
YoY Change	-12.86%	-10.0%	-3.92%
% of Gross Profit
Operating Expenses	$24.00M	$84.51M	$18.56M
YoY Change	29.32%	30.58%	25.41%
Operating Profit		-$73.52M
YoY Change		27.19%
Interest Expense	-$525.0K	$2.857M	-$870.0K
YoY Change	-39.66%	-28.77%	-92.48%
% of Operating Profit
Other Income/Expense, Net		-$2.725M
YoY Change		-54.12%
Pretax Income	-$21.32M	-$7.700M	-$17.04M
YoY Change	25.12%	-87.92%	-30.87%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$21.32M	-$76.25M	-$17.04M
YoY Change	25.12%	19.61%	-30.88%
Net Earnings / Revenue	-665.03%	-693.91%	-712.97%
Basic Earnings Per Share		-$0.83
Diluted Earnings Per Share	-$159.8K	-$0.83	-$197.4K
COMMON SHARES
Basic Shares Outstanding	135.3M shares	106.2M shares	84.91M shares
Diluted Shares Outstanding		106.2M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$155.3M	$155.3M	$123.3M
YoY Change	26.0%	25.97%	35.71%
Cash & Equivalents	$109.3M	$109.3M	$52.25M
Short-Term Investments	$46.04M	$46.04M	$71.02M
Other Short-Term Assets	$4.445M	$4.445M	$3.100M
YoY Change	43.39%	43.39%	72.22%
Inventory
Prepaid Expenses
Receivables	$899.0K	$899.0K	$1.312M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$160.7M	$160.7M	$127.7M
YoY Change	25.81%	25.81%	36.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.983M	$8.075M	$6.927M
YoY Change	-13.63%	-13.17%	-20.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$35.69M	$0.00
YoY Change
Other Assets	$61.00K	$61.00K	$44.00K
YoY Change	38.64%		-84.98%
Total Long-Term Assets	$43.82M	$43.82M	$9.376M
YoY Change	367.41%	366.21%	-19.91%
TOTAL ASSETS
Total Short-Term Assets	$160.7M	$160.7M	$127.7M
Total Long-Term Assets	$43.82M	$43.82M	$9.376M
Total Assets	$204.5M	$204.5M	$137.1M
YoY Change	49.17%	49.15%	29.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.174M	$3.174M	$3.000M
YoY Change	5.8%	5.8%	25.0%
Accrued Expenses	$8.021M	$8.021M	$6.300M
YoY Change	27.32%	27.32%	21.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.22M	$11.22M	$9.541M
YoY Change	17.61%	18.12%	21.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$23.83M	$23.83M	$25.60M
YoY Change	-6.93%	-6.93%	2.4%
Total Long-Term Liabilities	$23.83M	$23.83M	$25.60M
YoY Change	-6.93%	-6.93%	2.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.22M	$11.22M	$9.541M
Total Long-Term Liabilities	$23.83M	$23.83M	$25.60M
Total Liabilities	$35.05M	$35.05M	$35.11M
YoY Change	-0.19%	-0.15%	7.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.134B		-$1.046B
YoY Change	8.45%		7.82%
Common Stock	$1.287B		$985.9M
YoY Change	30.5%		9.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$169.4M	$169.4M	$102.0M
YoY Change
Total Liabilities & Shareholders Equity	$204.5M	$204.5M	$137.1M
YoY Change	49.17%	49.15%	29.89%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$21.32M	-$76.25M	-$17.04M
YoY Change	25.12%	19.61%	-30.88%
Depreciation, Depletion And Amortization	$427.0K	$1.800M	$490.0K
YoY Change	-12.86%	-10.0%	-3.92%
Cash From Operating Activities	-$19.61M	-$67.53M	-$15.01M
YoY Change	30.62%	31.28%	12.43%
INVESTING ACTIVITIES
Capital Expenditures	-$58.00K	$809.0K	-$150.0K
YoY Change	-61.33%	253.28%	150.0%
Acquisitions
YoY Change
Other Investing Activities	-$8.063M	-$11.87M	-$49.82M
YoY Change	-83.82%	-19.15%	-15.21%
Cash From Investing Activities	-$8.121M	-$12.68M	-$49.98M
YoY Change	-83.75%	-14.96%	-15.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$134.7M
YoY Change		56.05%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	59.12M	$137.2M	20.21M
YoY Change	192.53%	58.2%	45.4%
NET CHANGE
Cash From Operating Activities	-19.61M	-$67.53M	-15.01M
Cash From Investing Activities	-8.121M	-$12.68M	-49.98M
Cash From Financing Activities	59.12M	$137.2M	20.21M
Net Change In Cash	31.39M	$57.03M	-44.78M
YoY Change	-170.11%	178.85%	-23.15%
FREE CASH FLOW
Cash From Operating Activities	-$19.61M	-$67.53M	-$15.01M
Capital Expenditures	-$58.00K	$809.0K	-$150.0K
Free Cash Flow	-$19.55M	-$68.34M	-$14.86M
YoY Change	31.55%	32.26%	11.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-34949
CY2021	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
CY2021	dei	City Area Code CityAreaCode	267
CY2021	dei	Local Phone Number LocalPhoneNumber	469-0914
CY2021	dei	Security12b Title Security12bTitle	Common shares, without par value
CY2021	dei	Trading Symbol TradingSymbol	ABUS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	238483586	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	148641736	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109282000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52251000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	46035000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	71017000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	899000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1312000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4445000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3124000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	160661000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	127704000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5983000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6927000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	35688000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2092000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2405000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	61000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44000	USD
CY2021Q4	us-gaap	Assets Assets	204485000	USD
CY2020Q4	us-gaap	Assets Assets	137080000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10838000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9151000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	383000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11221000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9541000	USD
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	USD
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2231000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2593000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	35046000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	35114000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2021Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	0	USD
CY2020Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	149408000	USD
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144987736	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144987736	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89678722	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89678722	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1286636000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	985939000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65485000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60751000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1134347000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1045961000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48335000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48171000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204485000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137080000	USD
CY2021	us-gaap	Revenues Revenues	10988000	USD
CY2020	us-gaap	Revenues Revenues	6914000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65502000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49338000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17136000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14845000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1872000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	473000	USD
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	64000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	84510000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	64720000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-73522000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-57806000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	127000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	741000	USD
CY2021	us-gaap	Interest Expense InterestExpense	2857000	USD
CY2020	us-gaap	Interest Expense InterestExpense	4011000	USD
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2545000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-124000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2725000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5939000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-76247000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63745000	USD
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12139000	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12123000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88386000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75868000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106242452	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106242452	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75835378	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75835378	shares
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-164000	USD
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	14000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-44000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76411000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63687000	USD
CY2020	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax Period Increase Decrease TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease	44000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	72744000	USD
CY2020	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6145000	USD
CY2020	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	18000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86297000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	449000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63745000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	USD
CY2021	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6385000	USD
CY2021	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	263000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134665000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	461000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2110000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-164000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-76247000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-76247000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63745000	USD
CY2021	us-gaap	Depreciation Depreciation	1753000	USD
CY2020	us-gaap	Depreciation Depreciation	1978000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6424000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6161000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	5000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	56000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1872000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	473000	USD
CY2021	abus	Netequityinvestmentgainorloss Netequityinvestmentgainorloss	0	USD
CY2020	abus	Netequityinvestmentgainorloss Netequityinvestmentgainorloss	2545000	USD
CY2021	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	6108000	USD
CY2020	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	3395000	USD
CY2021	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	2850000	USD
CY2020	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	3957000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-999000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-210000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-413000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	108000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1025000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	752000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1911000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1666000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-369000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-375000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67532000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51441000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	82219000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	85578000	USD
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	70350000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	73398000	USD
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2500000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	809000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	229000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12678000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14909000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2110000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	449000	USD
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	461000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	134665000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	86297000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137236000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86746000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57031000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20452000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52251000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31799000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109282000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52251000	USD
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	12139000	USD
CY2020	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	12123000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (“HBV”), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing an RNA interference (“RNAi”) therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (“cHBV”) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening, and is currently being evaluated in multiple phase 2 clinical trials. The Company has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses (including SARS-CoV-2). The Company is also exploring oncology applications for its internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company had an aggregate of $191.0 million in cash, cash equivalents and investments in marketable securities. In January 2022, the Company received a $40 million upfront payment and a $15 million equity investment from Qilu Pharmaceuticals Co., Ltd. (“Qilu”) as part of a technology transfer and exclusive licensing agreement to develop and commercialize AB-729 in China. The Company had no outstanding debt as of December 31, 2021. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact </span></div>The impact of the COVID-19 pandemic has been, and will likely continue to be, extensive in many aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling patients in new clinical trials. While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company’s plans and timelines in the future.
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	191000000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2021Q4	abus	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	2	subsidiary
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses and contingent liabilities as of the end or during the reporting period. Actual results could significantly differ from those estimates. Significant estimates in the accompanying consolidated financial statements impact contingent consideration, income tax recoveries, stock-based compensation, clinical trial accruals and the sale of future royalties liability.</span></div>
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31800000	shares
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
CY2021	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.0875
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></div>
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5300000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1900000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1872000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2953000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	473000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	81873000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	150000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	81723000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	71003000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	71017000	USD
CY2021Q4	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	2	lease
CY2021Q4	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P5Y
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	100000	USD
CY2020	abus	Fixed Lease Cost FixedLeaseCost	600000	USD
CY2021	abus	Fixed Lease Cost FixedLeaseCost	600000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	100000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	650000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	657000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	641000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	598000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	616000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	635000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	654000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	134000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3278000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	664000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2614000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15357000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9374000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5983000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14548000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7621000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6927000	USD
CY2021	us-gaap	Depreciation Depreciation	1800000	USD
CY2020	us-gaap	Depreciation Depreciation	2000000	USD
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3174000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2994000	USD
CY2021Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	4279000	USD
CY2020Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3566000	USD
CY2021Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2371000	USD
CY2020Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1653000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	983000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	679000	USD
CY2021Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	26000	USD
CY2020Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	250000	USD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
	abus	Maximum Contribution For Product MaximumContributionForProduct	7200000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10838000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9151000	USD
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	USD
CY2019Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	18992000	USD
CY2021	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	6108000	USD
CY2020	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	3395000	USD
CY2021	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	2850000	USD
CY2020	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	3957000	USD
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	USD
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9300000	CAD
CY2021	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2700000	USD
CY2021	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3700000	CAD
CY2021	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2021Q4	abus	Alnylam Entitlements AlnylamEntitlements	2	product
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2021	us-gaap	Revenues Revenues	10988000	USD
CY2020	us-gaap	Revenues Revenues	6914000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares
CY2021Q4	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	1500000	shares
CY2021Q4	abus	Common Stock Discount On Shares Percentage CommonStockDiscountOnSharesPercentage	0.15
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	196335	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1303665	shares
CY2021	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	300000	USD
CY2020	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	200000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6424000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6161000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11600000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23864000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17211000	USD
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1041000	USD
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	390000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	4292000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	622000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15928000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12033000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Investment IncomeTaxReconciliationTaxCreditsInvestment	611000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Investment IncomeTaxReconciliationTaxCreditsInvestment	0	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4840000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3716000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	456000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	450000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7700000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3800000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3900000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-80700000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-80700000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1800000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-61900000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	90255000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	74351000	USD
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16968000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15812000	USD
CY2021Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	634000	USD
CY2020Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	737000	USD
CY2021Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	4400000	USD
CY2020Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	5279000	USD
CY2021Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	549000	USD
CY2020Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	627000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3375000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3375000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3741000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3897000	USD
CY2021Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	3309000	USD
CY2020Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	2457000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1341000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1218000	USD
CY2021Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	130724000	USD
CY2020Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	114795000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	130724000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	114795000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares

Files In Submission

Name	View Source	Status
0001447028-22-000019-index-headers.html	Edgar Link	pending
0001447028-22-000019-index.html	Edgar Link	pending
0001447028-22-000019.txt	Edgar Link	pending
0001447028-22-000019-xbrl.zip	Edgar Link	pending
abus-20211231.htm	Edgar Link	pending
abus-20211231.xsd	Edgar Link	pending
abus-20211231_cal.xml	Edgar Link	unprocessable
abus-20211231_def.xml	Edgar Link	unprocessable
abus-20211231_g1.jpg	Edgar Link	pending
abus-20211231_g2.gif	Edgar Link	pending
abus-20211231_htm.xml	Edgar Link	completed
abus-20211231_lab.xml	Edgar Link	unprocessable
abus-20211231_pre.xml	Edgar Link	unprocessable
exhibit104-arbutusindemnit.htm	Edgar Link	pending
exhibit1041qilulicenseagre.htm	Edgar Link	pending
exhibit211listingofsubsidi.htm	Edgar Link	pending
exhibit231eyconsent2021.htm	Edgar Link	pending
exhibit31110-kcertceo2021.htm	Edgar Link	pending
exhibit31210-kcertcfo2021.htm	Edgar Link	pending
exhibit321soxcertceo2021.htm	Edgar Link	pending
exhibit322soxcertcfo2021.htm	Edgar Link	pending
exhibit41descriptionofsecu.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2021 Q4 Form 10-K Financial Statement

#000144702822000019 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2021 Q4 Form 10-K Financial Statement

#000144702822000019 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus